Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · IEX Real-Time Price · USD
42.55
-0.23 (-0.54%)
At close: Jul 19, 2024, 4:00 PM
42.50
-0.05 (-0.12%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,276 employees as of December 31, 2023. The number of employees decreased by 35 or -2.67% compared to the previous year.
Employees
1,276
Change (1Y)
-35
Growth (1Y)
-2.67%
Revenue / Employee
$346,854
Profits / Employee
-$480,683
Market Cap
3.85B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,276 | -35 | -2.67% |
Dec 31, 2022 | 1,311 | 192 | 17.16% |
Dec 31, 2021 | 1,119 | 226 | 25.31% |
Dec 31, 2020 | 893 | 153 | 20.68% |
Dec 31, 2019 | 740 | 130 | 21.31% |
Dec 31, 2018 | 610 | 90 | 17.31% |
Dec 31, 2017 | 520 | 144 | 38.30% |
Dec 31, 2016 | 376 | 127 | 51.00% |
Dec 31, 2015 | 249 | 142 | 132.71% |
Dec 31, 2014 | 107 | 48 | 81.36% |
Dec 31, 2013 | 59 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Surgery Partners | 13,500 |
Integer Holdings | 10,500 |
Perrigo Company | 9,140 |
Sotera Health Company | 3,000 |
Guardant Health | 1,779 |
Waystar Holding | 1,400 |
Inspire Medical Systems | 1,011 |
Axsome Therapeutics | 545 |
RARE News
- 2 days ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 weeks ago - Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA) - GlobeNewsWire
- 5 weeks ago - Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) - GlobeNewsWire
- 6 weeks ago - Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 2 months ago - Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference - GlobeNewsWire